My PCR
Create Account
Logo PCR

21 May 2026

Tricuspid / Pulmonary valveTAVIMitral valve replacement and repair

The continuum of valvular heart disease: a lifetime management approach

Sponsored by Abbott

Anchorperson: P. Lurz
Spokesperson: A. Latib
SHOW MORE

Summary

This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing and interventional strategies guided by recent clinical trials and updated guidelines, while also exploring next-generation valve technologies designed for complex patient profiles.

Learning Objectives

  • To understand how to plan for the lifetime management of valvular heart disease, and how intervention on one valve - aortic, mitral, or tricuspid - influences disease progression, timing, and treatment strategies for other valves across the full patient journey
  • To evaluate optimal timing and interventional strategies in aortic, mitral, and tricuspid valve disease, integrating contemporary evidence from pivotal clinical trials to inform patient‑centered treatment decisions
  • To apply updated clinical guidelines and emerging valve technologies to the treatment of valvular heart disease, optimising therapeutic strategies for increasingly complex patient profiles
Related Content
TMVR in 2026: expanding frontiers in transcatheter mitral therapy Tricuspid Regurgitation: when to suspect, when to worry, when to act TAVI Essentials: From patient selection to procedural success
Recommended for you
Register for the PCR Fundamentals Course London 2026 TRI‑FR: 2-year outcomes after transcatheter tricuspid repair ENCIRCLE: 1-year outcomes of TMVR with the SAPIEN M3 system for patients unsuitable for surgery